Susquehanna International Group
GNMX

Susquehanna International Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Susquehanna International Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,200
Closed -$74K – 10485
2016
Q4 		$74K Buy
+14,200
New +$74.7K ﹤0.01% 9194
2015
Q3 		– Sell
-12,900
Closed -$79K – 10499
2015
Q2 		$79K Sell
12,900
-400
-3% -$3.1K ﹤0.01% 9754
2015
Q1 		$107K Buy
+13,300
New +$100K ﹤0.01% 8943

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group's GNMX Position: Q2 2019 in Review

Susquehanna International Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2019, closing a stake of 127,313 shares — an estimated $25K sold.

Susquehanna International Group first reported a position in GNMX in Q1 2014 and held it in 13 quarters. The position peaked at $412K in Q1 2015. 29 funds tracked by Wall St. Rank hold GNMX as of Q2 2019.

  • Susquehanna International Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2019 after selling out during the quarter.
  • Susquehanna International Group sold 127,313 Aevi Genomic Medicine Inc shares in Q2 2019, an estimated $25K.
  • Susquehanna International Group first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 13 quarters.
  • Susquehanna International Group's Aevi Genomic Medicine Inc position peaked at $412K in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2019.

Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.